NOVARTIS

Novartis says the regulatory phase‑III trials Remodel‑1 and Remodel‑2 with the oral BTK inhibitor remibrutinib showed a significantly greater reduction in relapse rate compared with teriflunomide. Specifically, the company reported roughly one relapse over 13 years. The safety profile was described as robust, with no liver safety signals observed. The data were presented at the MSToronto2026 conference. » Więcej na finanzen.net

The FDA has approved Novartis’s Rhapsido (Remibrutinib) for the treatment of symptomatic dermographism in the US, extending its indication beyond chronic spontaneous urticaria. In the phase‑III RemIND study, twice as many adults treated with Rhapsido achieved complete resolution of hives by week 12 compared with placebo. Rhapsido is now the only medicine indicated for these two most common forms of chronic hives. Novartis shares fell as much as about 1.07 percent to 118.74 francs on the SIX. » Więcej na finanzen.net

Novartis is presenting, among other things, the regulatory‑relevant Remodel‑1 and Remodel‑2 studies on remibrutinib at the MSToronto2026 congress (presentation on 23 October). Other late‑breaking abstracts cover Kesimpta (ofatumumab) in pediatrics (Phase III study Neos), the Sthenos study in treatment‑naive patients, and pregnancy and breastfeeding data from Prim and Katharos. The programme includes a total of 46 abstracts. On the SIX the stock reacted with gains, rising temporarily by around 1.19% to CHF 118.58. » Więcej na finanzen.net